Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cartesian Therapeutics ( (RNAC) ) just unveiled an update.
On March 26, 2026, Cartesian Therapeutics, Inc. disclosed that Board member Murat Kalayoglu, M.D., Ph.D., intends to resign from the Board effective March 31, 2026, after serving since 2023. Kalayoglu, who chaired the Science and Technology Committee and sat on the Nominating and Corporate Governance Committee, is leaving to pursue other opportunities, and the company emphasized that his departure does not stem from any disagreement over its operations, policies or practices.
With his resignation, Kalayoglu will also step down from his committee roles, prompting a reshuffle of scientific and governance oversight within the boardroom. Cartesian publicly thanked him for his advice and leadership, signaling an orderly transition that, while removing an experienced scientific voice from the board, is not expected to indicate internal conflict or immediate disruption for stakeholders.
The most recent analyst rating on (RNAC) stock is a Sell with a $5.50 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.
Spark’s Take on RNAC Stock
According to Spark, TipRanks’ AI Analyst, RNAC is a Neutral.
The score is held down primarily by deteriorating financial performance (sharp revenue compression, widening losses, and heavy cash burn with negative equity) and a bearish technical trend (below major moving averages with negative MACD). A positive corporate update and stated cash runway into mid-2027 provide some offset, but valuation support is limited due to ongoing losses and no dividend yield data.
To see Spark’s full report on RNAC stock, click here.
More about Cartesian Therapeutics
Cartesian Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutic products, leveraging advanced scientific and technological expertise. The company operates in a highly specialized segment of the life sciences industry, where board-level oversight of science, technology and corporate governance is critical to its strategic direction and R&D execution.
Average Trading Volume: 187,135
Technical Sentiment Signal: Sell
Current Market Cap: $155.1M
See more data about RNAC stock on TipRanks’ Stock Analysis page.